Journal Article

The Streptococcus pyogenes vaccine landscape

Steer, Andrew C, Mullin, Anne E, Kim, Jerome H, Walkinshaw, Donald R, Wright, Meghan E. E, Excler, Jean-Louis

2023

Overview

Recent efforts have re-invigorated the Streptococcus pyogenes (Group A Streptococcus) vaccine development field, though scientific, regulatory and commercial barriers persist, and the vaccine pipeline remains sparse. There is an ongoing need to accelerate all aspects of development to address the large global burden of disease caused by the pathogen. Building on over 100 years of S. pyogenes vaccine development, there are currently eight candidates on a product development track, including four M protein-based candidates and four candidates designed around non-M protein antigens. These candidates have demonstrated proof of concept for protection against S. pyogenes in preclinical models, one has demonstrated safety and immunogenicity in a Phase 1 trial and at least four others are poised to soon enter clinical trials. To maintain momentum, the Strep A Vaccine Global Consortium (SAVAC) was established to bring together experts to accelerate global S. pyogenes vaccine development. This article highlights the past, present and future of S. pyogenes vaccine development and emphasizes key priorities, and the role of SAVAC, in advancing the field.

• Publisher: Nature Publishing Group
• Subject: Immunogenicity / Medical research / Pharmaceutical industry / Product development / Streptococcus infections / Vaccines